|
Gene: PBRM1 |
Gene summary for PBRM1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PBRM1 | Gene ID | 55193 |
Gene name | polybromo 1 | |
Gene Alias | BAF180 | |
Cytomap | 3p21.1 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q86U86 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55193 | PBRM1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.43e-13 | -5.34e-01 | 0.0155 |
55193 | PBRM1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.82e-05 | -4.32e-01 | 0.096 |
55193 | PBRM1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.80e-03 | -3.16e-01 | 0.0674 |
55193 | PBRM1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.38e-04 | -4.57e-01 | 0.0588 |
55193 | PBRM1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.17e-02 | -5.27e-01 | 0.2585 |
55193 | PBRM1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.84e-09 | -4.44e-01 | 0.3005 |
55193 | PBRM1 | A001-C-207 | Human | Colorectum | FAP | 3.61e-02 | -1.53e-01 | 0.1278 |
55193 | PBRM1 | A015-C-203 | Human | Colorectum | FAP | 2.22e-25 | -2.96e-01 | -0.1294 |
55193 | PBRM1 | A015-C-204 | Human | Colorectum | FAP | 4.35e-05 | -2.05e-01 | -0.0228 |
55193 | PBRM1 | A014-C-040 | Human | Colorectum | FAP | 1.75e-04 | -3.89e-01 | -0.1184 |
55193 | PBRM1 | A002-C-201 | Human | Colorectum | FAP | 1.27e-14 | -2.71e-01 | 0.0324 |
55193 | PBRM1 | A002-C-203 | Human | Colorectum | FAP | 1.23e-04 | -1.45e-01 | 0.2786 |
55193 | PBRM1 | A001-C-119 | Human | Colorectum | FAP | 5.29e-06 | -2.59e-01 | -0.1557 |
55193 | PBRM1 | A001-C-108 | Human | Colorectum | FAP | 5.43e-16 | -9.82e-02 | -0.0272 |
55193 | PBRM1 | A002-C-205 | Human | Colorectum | FAP | 1.41e-20 | -2.44e-01 | -0.1236 |
55193 | PBRM1 | A015-C-006 | Human | Colorectum | FAP | 3.93e-15 | -3.28e-01 | -0.0994 |
55193 | PBRM1 | A015-C-106 | Human | Colorectum | FAP | 2.14e-11 | -1.81e-01 | -0.0511 |
55193 | PBRM1 | A002-C-114 | Human | Colorectum | FAP | 2.83e-17 | -1.46e-01 | -0.1561 |
55193 | PBRM1 | A015-C-104 | Human | Colorectum | FAP | 2.48e-31 | -2.17e-01 | -0.1899 |
55193 | PBRM1 | A001-C-014 | Human | Colorectum | FAP | 1.47e-13 | -1.36e-01 | 0.0135 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
GO:00063253 | Colorectum | FAP | chromatin organization | 84/2622 | 409/18723 | 1.62e-04 | 2.47e-03 | 84 |
GO:00063254 | Colorectum | CRC | chromatin organization | 74/2078 | 409/18723 | 1.48e-05 | 4.61e-04 | 74 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:00063255 | Liver | NAFLD | chromatin organization | 64/1882 | 409/18723 | 2.31e-04 | 3.89e-03 | 64 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:00063256 | Lung | IAC | chromatin organization | 69/2061 | 409/18723 | 2.01e-04 | 3.53e-03 | 69 |
GO:000632512 | Lung | AIS | chromatin organization | 62/1849 | 409/18723 | 4.24e-04 | 7.29e-03 | 62 |
GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
GO:00063383 | Oral cavity | EOLP | chromatin remodeling | 46/2218 | 255/18723 | 2.34e-03 | 1.44e-02 | 46 |
GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
GO:00063382 | Prostate | BPH | chromatin remodeling | 62/3107 | 255/18723 | 9.47e-04 | 5.97e-03 | 62 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
GO:000632518 | Skin | AK | chromatin organization | 73/1910 | 409/18723 | 1.40e-06 | 4.26e-05 | 73 |
GO:00063384 | Skin | AK | chromatin remodeling | 51/1910 | 255/18723 | 1.95e-06 | 5.73e-05 | 51 |
GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa052252 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
hsa052253 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
hsa052254 | Colorectum | FAP | Hepatocellular carcinoma | 43/1404 | 168/8465 | 1.78e-03 | 8.99e-03 | 5.47e-03 | 43 |
hsa052255 | Colorectum | FAP | Hepatocellular carcinoma | 43/1404 | 168/8465 | 1.78e-03 | 8.99e-03 | 5.47e-03 | 43 |
hsa052256 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa052257 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa052259 | Lung | IAC | Hepatocellular carcinoma | 33/1053 | 168/8465 | 4.77e-03 | 2.15e-02 | 1.43e-02 | 33 |
hsa0522512 | Lung | IAC | Hepatocellular carcinoma | 33/1053 | 168/8465 | 4.77e-03 | 2.15e-02 | 1.43e-02 | 33 |
hsa0522521 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0522531 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0522541 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa0522551 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa0522516 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa0522517 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PBRM1 | SNV | Missense_Mutation | c.1758G>A | p.Met586Ile | p.M586I | Q86U86 | protein_coding | tolerated(0.18) | possibly_damaging(0.718) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
PBRM1 | SNV | Missense_Mutation | c.1182G>C | p.Arg394Ser | p.R394S | Q86U86 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PBRM1 | SNV | Missense_Mutation | c.2908G>C | p.Glu970Gln | p.E970Q | Q86U86 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
PBRM1 | SNV | Missense_Mutation | c.4339G>C | p.Gly1447Arg | p.G1447R | Q86U86 | protein_coding | deleterious(0.02) | benign(0.405) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PBRM1 | SNV | Missense_Mutation | c.4296N>A | p.Met1432Ile | p.M1432I | Q86U86 | protein_coding | tolerated(0.4) | benign(0) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PBRM1 | insertion | Nonsense_Mutation | novel | c.422_423insAACCC | p.Trp141Ter | p.W141* | Q86U86 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
PBRM1 | insertion | Frame_Shift_Ins | novel | c.420_421insGGGAGGCTGAGGCAGGAGAATCGCT | p.Trp141GlyfsTer18 | p.W141Gfs*18 | Q86U86 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
PBRM1 | insertion | Frame_Shift_Ins | novel | c.3486_3487insTTAGGGCACAACCAAACCTTTCACCTCAGCCTTCCAAGTT | p.Ala1163LeufsTer31 | p.A1163Lfs*31 | Q86U86 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
PBRM1 | insertion | Frame_Shift_Ins | novel | c.773dupA | p.Asn258LysfsTer6 | p.N258Kfs*6 | Q86U86 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PBRM1 | insertion | Nonsense_Mutation | novel | c.2011_2012insGCTTATCCACAATCTTTTTGTGTCAGTCATGAGT | p.Asn671SerfsTer11 | p.N671Sfs*11 | Q86U86 | protein_coding | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55193 | PBRM1 | CLINICALLY ACTIONABLE | inhibitor | 249565598 | ||
55193 | PBRM1 | CLINICALLY ACTIONABLE | ALPRAZOLAM | ALPRAZOLAM | 22137933 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | ATEZOLIZUMAB | ATEZOLIZUMAB | 29301960 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | CTLA-4 INHIBITOR | 29301960 | ||
55193 | PBRM1 | CLINICALLY ACTIONABLE | ANTI-PD-L1 MONOCLONAL ANTIBODY | 29301960 | ||
55193 | PBRM1 | CLINICALLY ACTIONABLE | NIVOLUMAB | NIVOLUMAB | 29301960,31486842 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | EVEROLIMUS | EVEROLIMUS | 27751729 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | IPILIMUMAB | IPILIMUMAB | 29301960 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | TRIAZOLAM | TRIAZOLAM | 22137933 | |
55193 | PBRM1 | CLINICALLY ACTIONABLE | SUNITINIB | SUNITINIB | 27751729 |
Page: 1 2 |